The vial in the fridge that nobody thinks about anymore

The box arrived on a Tuesday, the way it always had. Multidose vials of compounded semaglutide, packed in a cooler, restocked into the little clinical refrigerator behind the front desk of a busy aesthetics clinic just off the Dallas North Tollway. For two years that fridge was a profit engine. Then the rules changed, the fridge emptied, and everyone moved on to branded product — or so it felt. What almost no owner in North Texas is thinking about is that the risk did not leave when the vials did. It is still sitting in the charts. This crackdown reached deep into Texas: the federal lawsuits challenging the FDA’s shortage decisions were filed in the U.S. District Court for the Northern District of Texas, and the court denied the compounders’ request to block the FDA in April 2025. For med spas from Frisco and Plano to McKinney and Prosper, the compliance headlines have been loud — but the coverage question underneath them has been nearly silent. This guide is about that quieter question. Proverbs 27:12 puts it plainly: a prudent man foreseeth the evil, and hideth himself; but the simple pass on, and are punished.

What the “compounding cliff” actually is

Start with first principles. Compounding is not the same thing as manufacturing. Under federal law, a pharmacy could produce a copy of an FDA-approved drug only under narrow conditions — and one of those conditions was that the drug appeared on the FDA’s official shortage list. Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) landed on that shortage list in 2022 when demand outran supply. That single listing is what opened the door to an entire industry of cheaper compounded weight-loss shots.

Then the door closed. The FDA determined the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025. Once a drug leaves the shortage list, the statutory exception that permitted “essentially a copy” compounding expires, and the FDA set staged wind-down deadlines through the spring of 2025 for both state-licensed pharmacies (503A) and larger outsourcing facilities (503B). In April 2026, the agency went further and proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the mechanism that could have allowed bulk compounding to resume outside of a shortage. In plain terms: the temporary bridge that the compounded-GLP-1 business was built on is being dismantled, and the FDA has signaled it does not intend to rebuild it.

For an insurance conversation, the mechanics matter less than the consequence. When a regulator reclassifies an activity from “permitted” to “prohibited,” general liability and professional liability underwriters follow close behind — and they follow with exclusions.

The Texas reality: a shot is the practice of medicine

Here is the piece that turns a national drug-policy story into a Texas liability story. In Texas, administering a weight-loss injection is a medical act, not a spa service. The Texas Medical Board treats these procedures as the practice of medicine, which means a physician, physician assistant, or advanced practice registered nurse generally must perform a Good Faith Exam and establish the treatment order before a delegated provider gives the injection. According to the Texas Medical Board’s own guidance to physicians, the board continues to encounter med spa businesses with no physician involvement or inadequate physician involvement — and it has made clear those rules are actively enforced.

Why does that matter for coverage? Because a professional liability policy insures you for negligence within your licensed and delegated scope of practice. If an injection was administered without a compliant Good Faith Exam, a carrier defending a claim has a ready-made argument that the act fell outside the covered scope — a distinction that can separate a defended claim from a denied one. The exact requirements, including any conditions on telehealth exams, should be confirmed directly with the Texas Medical Board and your healthcare attorney; the rules have been reorganized recently and continue to draw enforcement attention. This is also where the difference between medical malpractice and general liability coverage stops being academic: a slip-and-fall in your lobby and a bad clinical outcome from a compounded drug are covered by two different policies, with two different sets of exclusions.

Mistakes & myths that create uncovered gaps

• Myth: “We stopped offering compounded GLP-1s, so the exposure is gone.” Reality: the exposure is not gone — it is delayed. Bodily-injury claims can surface months or years after treatment. If your professional liability is written on a claims-made basis, coverage generally responds only if the policy is active when the claim is made — not when the treatment happened. Drop the policy or let a GLP-1 exclusion attach at renewal, and a claim over a 2024 dose can find you with no coverage behind it.
• Myth: “My general liability policy covers everything the business does.” Reality: general liability typically covers premises and bodily injury from operations, but injury arising from a professional medical service usually needs professional liability or malpractice coverage. Relying on the wrong policy is one of the most common — and most expensive — coverage misreads a med spa can make.
• Myth: “If I’m sued, my carrier will just handle it.” Reality: many carriers have added specific exclusions for semaglutide, tirzepatide, and compounded versions. An exclusion is not a gray area — it is a written instruction that the carrier will not defend that claim.
• Myth: “Selling my med spa ends my liability.” Reality: without tail coverage, past acts can remain your personal responsibility after you switch carriers, sell, or retire. The tail is the bridge — and it has to be bought deliberately.

The numbers: where a claim actually lands

The point of the table below is not to quote a premium — every med spa is underwritten individually, and rates vary by carrier, services, providers, and claims history. The point is to show who pays depending on how your coverage is structured when a claim tied to a past compounded dose arrives.

None of these outcomes is a guarantee — coverage always turns on your specific policy language and the facts of the claim. That uncertainty is exactly the argument for having someone read the actual forms before a claim, not after.

The Agent’s Office® advantage

As an independent agency representing dozens of carriers, we are not here to defend one company’s policy form — we are here to read yours. For a North Texas med spa, that means three concrete things: comparing how different carriers treat GLP-1 and compounded-drug exposure, checking whether your professional liability is claims-made or occurrence and whether tail coverage is in place, and making sure your business owner’s policy and malpractice coverage line up with what your medical office lease actually requires. We serve clients across North Texas by phone, text, and email — you never have to leave your clinic to get a straight answer. We architect protection; we do not just sell a policy. And to be clear about our lane: we can help you structure and compare coverage, but questions of legal compliance and medical scope of practice belong with your healthcare attorney and the Texas Medical Board.